Disease specific characteristics of fetal epigenetic markers for non-invasive prenatal testing of trisomy 21

BMC Medical Genomics

Hyun Mee Ryu¹  Moon Young Kim¹  You Jung Han¹  Hyun Kyong Ahn¹  Do Jin Kim²  So Yeon Park²  Da Eun Lee²  Ji Hyae Lim² 

[1] Department of Obstetrics and Gynecology, Cheil General Hospital and Women’s Healthcare Center, Kwandong University College of Medicine, Seoul, Korea;Laboratory of Medical Genetics, Medical Research Institute, Cheil General Hospital and Women’s Healthcare Center, Seoul, Korea

关键词: Epigenetic markers;    Non-invasive prenatal testing;    Trisomy 21;   

Others  :  1091068
DOI  :  10.1186/1755-8794-7-1

 received in 2013-10-02, accepted in 2014-01-05,  发布年份 2014

【 摘 要 】

Background

Non-invasive prenatal testing of trisomy 21 (T21) is being actively investigated using fetal-specific epigenetic markers (EPs) that are present in maternal plasma. Recently, 12 EPs on chromosome 21 were identified based on tissue-specific epigenetic characteristics between placenta and blood, and demonstrated excellent clinical performance in the non-invasive detection of fetal T21. However, the disease-specific epigenetic characteristics of the EPs have not been established. Therefore, we validated the disease-specific epigenetic characteristics of these EPs for use in non-invasive detection of fetal T21.

Methods

We performed a high-resolution tiling array analysis of human chromosome 21 using a methyl-CpG binding domain-based protein (MBD) method with whole blood samples from non-pregnant normal women, whole blood samples from pregnant normal women, placenta samples of normal fetuses, and placenta samples of T21 fetuses. Tiling array results were validated by bisulfite direct sequencing and qPCR.

Results

Among 12 EPs, only four EPs were confirmed to be hypermethylated in normal placenta and hypomethylated in blood. One of these four showed a severe discrepancy in the methylation patterns of T21 placenta samples, and another was located within a region of copy number variations. Thus, two EPs were confirmed to be potential fetal-specific markers based on their disease-specific epigenetic characteristics. The array results of these EPs were consisted with the results obtained by bisulfite direct sequencing and qPCR. Moreover, the two EPs were detected in maternal plasma.

Conclusions

We validated that two EPs have the potential to be fetal-specific EPs which is consistent with their disease-specific epigenetic characteristics. The findings of this study suggest that disease-specific epigenetic characteristics should be considered in the development of fetal-specific EPs for non-invasive prenatal testing of T21.

【 授权许可】

   
2014 Lim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Grimshaw GM, Szczepura A, Hultén M, MacDonald F, Nevin NC, Sutton F, Dhanjal S: Evaluation of molecular tests for prenatal diagnosis of chromosome abnormalities. Health Technol Assess 2003, 7:1-146.
• [2]Mégarbané A, Ravel A, Mircher C, Sturtz F, Grattau Y, Rethoré MO, Delabar JM, Mobley WC: The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome. Genet Med 2009, 11:611-616.
• [3]ACOG Committee on Practice Bulletins: ACOG practice bulletin no. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007, 109:217-227.
• [4]Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D’Alton ME, First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium: First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 2005, 353:2001-2011.
• [5]Nicolaides KH: Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004, 191:45-67.
• [6]Rozenberg P, Bussières L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialard F, Giudicelli Y, Ville Y: Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol 2006, 195:1379-1387.
• [7]American College of Obstetricians and Gynecologists: ACOG practice bulletin No. 88, December 2007. Invasive prenatal testing for aneuploidy. Obstet Gynecol 2007, 110:1459-1467.
• [8]Alfirevic Z, Sundberg K, Brigham S: Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003., 3CD003252
• [9]Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350:485-487.
• [10]Lun FM, Chiu RW, Allen Chan KC, Yeung Leung T, Kin Lau T, Dennis Lo YM: Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. Clin Chem 2008, 54:1664-1672.
• [11]Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM: Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999, 64:218-224.
• [12]Lo YM, Chan KC, Sun H, Chen EZ, Jiang P, Lun FM, Zheng YW, Leung TY, Lau TK, Cantor CR, Chiu RW: Maternal plasma DNA sequencing reveals the genome wide genetic and mutational profile of the fetus. Sci Transl Med 2010, 2:61ra91.
• [13]Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, Van den Boom D: Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011, 204(205):e1-e11.
• [14]Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP: MatErnal BLood IS source to accurately diagnose fetal aneuploidy (MELISSA) study group: genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012, 119:890-901.
• [15]Lim JH, Park SY, Ryu HM: Non-invasive prenatal diagnosis of fetal trisomy 21 using cell-free fetal DNA in maternal blood. Obstet Gynecol Sci 2013, 56:58-66.
• [16]Mersy E, Smits LJ, van Winden LA, de Die-Smulders CE, South-East Netherlands NIPT C, Paulussen AD, Macville MV, Coumans AB, Frints SG: Noninvasive detection of fetal trisomy 21: systematic review and report of quality and outcomes of diagnostic accuracy studies performed between 1997 and 2012. Hum Reprod Update 2013, 19:318-329.
• [17]Lim JH, Kim SY, Park SY, Lee SY, Kim MJ, Han YJ, Lee SW, Chung JH, Kim MY, Yang JH, Ryu HM: Non-invasive epigenetic detection of fetal trisomy 21 in first trimester maternal plasma. PLoS One 2011, 6:e27709.
• [18]Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC: Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med 2011, 17:510-513.
• [19]Papageorgiou EA, Fiegler H, Rakyan V, Beck S, Hulten M, Lamnissou K, Carter NP, Patsalis PC: Sites of differential DNA methylation between placenta and peripheral blood: molecular markers for noninvasive prenatal diagnosis of aneuploidies. Am J Pathol 2009, 174:1609-1618.
• [20]Jiang M, Zhang Y, Fei J, Chang X, Fan W, Qian X, Zhang T, Lu D: Rapid quantification of DNA methylation by measuring relative peak heights in direct bisulfite-PCR sequencing traces. Lab Invest 2010, 90:282-290.
• [21]Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, Gehrke C: Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res 1982, 10:2709-2721.
• [22]Kerkel K, Schupf N, Hatta K, Pang D, Salas M, Kratz A, Minden M, Murty V, Zigman WB, Mayeux RP, Jenkins EC, Torkamani A, Schork NJ, Silverman W, Croy BA, Tycko B: Altered DNA methylation in leukocytes with trisomy 21. PLoS Genet 2010, 6:e1001212.
• [23]Wang SC, Oelze B, Schumacher A: Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One 2008, 3:e2698.
• [24]Kanwal R, Gupta S: Epigenetic modifications in cancer. Clin Genet 2012, 81:303-311.
• [25]Feinberg AP: Genome-scale approaches to the epigenetics of common human disease. Virchows Arch 2010, 456:13-21.
• [26]Tsaliki E, Papageorgiou EA, Spyrou C, Koumbaris G, Kypri E, Kyriakou S, Sotiriou C, Touvana E, Keravnou A, Karagrigoriou A, Lamnissou K, Velissariou V, Patsalis PC: MeDIP real-time qPCR of maternal peripheral blood reliably identifies trisomy 21. Prenat Diagn 2012, 32:996-1001.
• [27]Tong YK, Chiu RW, Chan KC, Leung TY, Lo YM: Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis. Nat Med 2012, 18:1327-1328.